Results 111 to 120 of about 18,687 (213)

Physiologically Based Pharmacokinetic Modeling to Assess Antiretroviral-BTK Inhibitor Interactions and Provide Recommendations for Co-Administration Regimens. [PDF]

Pharmaceutics
Chen L, Wang X, Li L, Yang Y, Liu Y, Chen W.   +5 more
europepmc   +1 more source

Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial. [PDF]

Nat Commun
Català-Moll F, Blázquez-Bondia C, Farré-Badia J, Torres F, Manzardo C, Bonfill E, Curran A, Domingo P, Podzamczer D, Force L, Falcó V, Parera M, Casadellà M, Miró JM, Noguera-Julian M, Paredes R, ADVANZ-4 MISTRAL investigators.   +16 more
europepmc   +1 more source

Effectiveness and safety of darunavir and lopinavir for treating children and adolescents living with HIV: a systematic review. [PDF]

BMC Infect Dis
O'Rourke J, Townsend CL, Milanzi E, Castro H, Collins IJ, Judd A, Jesson J, Leroy V, Penazzato M, Vicari M, Renaud F.   +10 more
europepmc   +1 more source

Reversible Effects of Integrase Inhibitors on Newly Differentiated Adipocytes. [PDF]

Viruses
Pickering RT, Asundi A, Olson A, Soden K, Lin NH.   +4 more
europepmc   +1 more source

Advancements in development of novel class of HIV protease inhibitors. [PDF]

Ann Med
Gu WG, Yin GZ, Zhang YP.
europepmc   +1 more source

Author Correction: Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial. [PDF]

Nat Commun
Català-Moll F, Blázquez-Bondia C, Farré-Badia J, Torres F, Manzardo C, Bonfill E, Curran A, Domingo P, Podzamczer D, Force L, Falcó V, Parera M, Casadellà M, Miró JM, Noguera-Julian M, Paredes R, ADVANZ-4 MISTRAL investigators.   +16 more
europepmc   +1 more source

Impact of HAART therapy on cognitive function in patients with HIV: a systematic review of randomized control trial. [PDF]

Ann Med Surg (Lond)
Al Diab Al Azzawi M, Alhamed AM, Almajed H, Ahmed WA, Alshahrani NNA, Idris IS, Aldayhani OB, Fallatah F, Bedaiwi RH.   +8 more
europepmc   +1 more source

Population pharmacokinetics of ritonavir as a booster of lopinavir, atazanavir, or darunavir in African children with HIV. [PDF]

Antimicrob Agents Chemother
Tsirizani L, Waalewijn H, Szubert A, Mulenga V, Chabala C, Bwakura-Dangarembizi M, Chitsamatanga M, Rutebarika DA, Musiime V, Kasozi M, Lugemwa A, McIlleron HM, Burger DM, Gibb DM, Colbers A, Denti P, Wasmann RE, CHAPAS-4 trial team.   +17 more
europepmc   +1 more source

Laser Microinterferometry for API Solubility and Phase Equilibria: Darunavir as a Case Example. [PDF]

Pharmaceutics
Makarova V, Mandrik M, Antonov S.
europepmc   +1 more source

Phenotypic impacts of treatment-selected mutations in HIV-2 protease on darunavir and lopinavir susceptibility: Evaluating genotypic HIV-2 drug resistance tools. [PDF]

PLOS Glob Public Health
Raugi DN, Nixon RS, Smith RA, Hawes SE, Diallo K, Diallo MB, Faye K, Diaw B, Sy MP, Sall F, Seydi M, Gottlieb GS, University of Washington-Senegal HIV-2 Study Group.   +12 more
europepmc   +1 more source